Patients not eligible for CFTR-modulators (CFTRm) in Europe: characteristics and distribution - Adult Cystic Fibrosis Conference, 2023

Treatment and management (2)

Chair(s): James D. Chalmers, Sarah Collins

Session type: Oral presentation

Patients not eligible for CFTR-modulators (CFTRm) in Europe: characteristics and distribution

Irene Tomarelli

EVENTS HOME

Previous presentation

Next presentation

Session content

The Neuropsychiatric Implications of CFTR Modulator Therapy in Cystic Fibrosis Patients: A Systematic Review and Analysis of Regulatory Data

Jacob O'connor

e-poster

A 5-year monocentric retrospective analysis of the use of Ceftazidim/Avibactam and Ceftolozane/Tazobactam in adult cystic fibrosis patients

Till Othmer

e-poster

Bacteriophage therapy in cystic fibrosis patients - a comprehensive analysis of the outcomes and statistics at the Eliava Phage Therapy Center

Mariam Dadiani

e-poster

HETEROGENEITY IN TREATMENT RESPONSE TO ELEXACAFTOR-TEZACAFTOR-IVACAFTOR IN PEOPLE WITH CYSTIC FIBROSIS

Federica Bellino

Outcomes of short-term modulatory therapy in adult cystic fibrosis

Aytekin Idikut

e-poster

CFTR Modulator Therapy Rescues CFTR and Lowers P2X7R-induced Inflammasome Activation of Airway Epithelial Cells

Debananda Gogoi

e-poster

Pulmonary exacerbation rates after three years of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis and severe lung disease

Daniela Savi

e-poster

Patients not eligible for CFTR-modulators (CFTRm) in Europe: characteristics and distribution

Irene Tomarelli

e-poster

Long-term effectiveness and safety of Elexacaftor/Tezacaftor/Ivacaftor in daily practice of a Portuguese Cystic Fibrosis Reference Centre

Elsa Guerreiro Da Cunha Fragoso

e-poster

Effect of elexacaftor/tezacaftor/ivacaftor on body plethysmography measurements in patients with cystic fibrosis and advanced lung disease.

Chiara Premuda

e-poster

#{title}